US 12,109,200 B2
Rifaximin
Dharmaraj Ramachandra Rao, Thane (IN); Rajendra Narayanrao Kankan, Mumbai (IN); Manjinder Singh Phull, Mumbai (IN); and Maruti Ghagare, Thane (IN)
Assigned to CIPLA LIMITED, Mumbai (IN)
Filed by CIPLA Limited, Mumbai (IN)
Filed on May 17, 2022, as Appl. No. 17/746,038.
Application 17/746,038 is a continuation of application No. 16/805,056, filed on Feb. 28, 2020, abandoned.
Application 16/805,056 is a continuation of application No. 15/873,342, filed on Jan. 17, 2018, granted, now 10,702,505, issued on Jul. 7, 2020.
Application 15/873,342 is a continuation of application No. 15/223,383, filed on Jul. 29, 2016, granted, now 9,877,953, issued on Jan. 30, 2018.
Application 15/223,383 is a continuation of application No. 14/733,786, filed on Jun. 8, 2015, granted, now 9,403,844, issued on Aug. 2, 2016.
Application 14/733,786 is a continuation of application No. 14/152,713, filed on Jan. 10, 2014, abandoned.
Application 14/152,713 is a continuation of application No. 12/441,368, granted, now 8,633,234, issued on Jan. 21, 2014, previously published as PCT/GB2007/003629, filed on Sep. 24, 2007.
Claims priority of application No. 1520/MUM/2006 (IN), filed on Sep. 22, 2006.
Prior Publication US 2023/0116935 A1, Apr. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 498/22 (2006.01); A61K 31/395 (2006.01); A61K 31/437 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/437 (2013.01) [C07D 498/22 (2013.01)] 4 Claims
 
1. A pharmaceutical composition in tablet form essentially free of crystalline rifaximin, the tablet comprising amorphous rifaximin, colloidal silicon dioxide, and microcrystalline cellulose.